Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F9 | P00740 | 8/20 | 0.65 |
| ▸ | C1S | P09871 | 3/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2482633 | 0.94 | F9 (0.71) | F9C1SSCN10ALRRK2GRM4 | |
| Trifluoroacetic Acid SCHEMBL1438252 | 0.85 | F9 (0.89) | F9C1SLRRK2GRM4 | |
| SCHEMBL1949096 | 0.80 | F9 (0.51) | F9SCN10AGRM4 | |
| Trifluoroacetic Acid SCHEMBL1947671 | 0.80 | F9 (0.66) | F9C1SLRRK2 | |
| SCHEMBL1950493 | 0.79 | F9 (1.00) | F9C1SLRRK2GRM4 | |
| SCHEMBL1947457 | 0.79 | F9 (1.00) | F9C1SLRRK2GRM4 | |
| Trifluoroacetic Acid SCHEMBL1945642 | 0.78 | F9 (0.72) | F9C1SLRRK2 | |
| Trifluoroacetic Acid SCHEMBL1947732 | 0.78 | F9 (0.90) | F9C1SLRRK2 | |
| Hydrochloric Acid SCHEMBL1946851 | 0.78 | F9 (0.98) | F9C1SLRRK2GRM4 | |
| Trifluoroacetic Acid SCHEMBL1950066 | 0.76 | F9 (0.75) | F9C1SLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373634-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2015-11-11 | — | — | EP | claimed |
| US-8642582-B2 | Morpholinone compounds as factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-02-04 | — | — | US | claimed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | claimed |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-10 | — | — | US | claimed |
| EP-2373634-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2015-11-11 | — | — | EP | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8642582-B2 | Morpholinone compounds as factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2373634-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | Mochida Pharmaceutical Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-10 | — | — | US | disclosed |
| WO-2010065717-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | F9 2/4885C1S 670/4885SLC2A1 4392/4885 |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | F9 2/4885C1S 670/4885SLC2A1 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.